PBC Screen: An IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis
Autor
Liu, H.; Norman, G. L.; Shums, Z.; Worman, H. J.; Krawitt, E. L.; Bizzaro, N.; Vergani, D.; Bogdanos, D. P.; Dalekos, G. N.; Milkiewicz, P.; Czaja, A. J.; Heathcote, E. J.; Hirschfield, G. M.; Tan, E. M.; Miyachi, K.; Bignotto, M.; Battezzati, P. M.; Lleo, A.; Leung, P. S.; Podda, M.; Gershwin, M. E.; Invernizzi, P.Datum
2010Schlagwort
Zusammenfassung
A dual isotype (IgG, IgA) enzyme-linked immunosorbent assay (ELISA) designed to provide enhanced detection of primary biliary cirrhosis (PBC)-specific autoantibodies against both major mitochondrial and nuclear antigens has been developed and recently become commercially available. The assay (PBC Screen) simultaneously detects IgG and IgA autoantibodies to the immunodominant portions of the 3 major mitochondrial (MIT3) and nuclear (gp210, and sp100) antigens. The aim of this study was to compare the performance of the PBC Screen to the combined performance obtained with individual IgG ELISAs to MIT3, gp210, and sp100 on a large group of selected patients from multiple centers. A total of 1175 patients with PBC and 1232 subjects without PBC were evaluated. Non-PBC groups included healthy controls (624) as well as individuals with autoimmune hepatitis (281), primary sclerosing cholangitis (77), viral hepatitis (91 hepatitis B and 98 hepatitis C), other liver diseases (31), and other infectious or autoimmune diseases (30). The PBC Screen at the receiver operator characteristic optimized cutoff of 27.8 units, had an overall sensitivity of 83.8%, specificity of 94.7% and area under curve of 0.9212. This was similar to the specificity of 96.1% obtained by the combined results of individual MIT3, sp100, and gp210 IgG ELISAs (kappa index at 0.898). Of the 253 PBC patients without AMA detectable by immunofluorescence, 113 (44.7%) were interpreted as positive for PBC-specific autoantibodies. In conclusion, the PBC Screen is an appropriate first-line test for the diagnosis of PBC, including for patients negative for markers assessed using conventional methods. © 2010 Elsevier Ltd.
Collections
Verwandte Dokumente
Anzeige der Dokumente mit ähnlichem Titel, Autor, Urheber und Thema.
-
Autoantibodies in autoimmune pancreatitis
Smyk, D. S.; Rigopoulou, E. I.; Koutsoumpas, A. L.; Kriese, S.; Burroughs, A. K.; Bogdanos, D. P. (2012)Autoimmune pancreatitis (AIP) was first used to describe cases of pancreatitis with narrowing of the pancreatic duct, enlargement of the pancreas, hyper - globulinaemia, and antinuclear antibody (ANA) positivity serologically. ... -
Diagnostic and clinical significance of Crohn's disease-specific pancreatic anti-GP2 and anti-CUZD1 antibodies
Pavlidis P., Komorowski L., Teegen B., Liaskos C., Koutsoumpas A.L., Smyk D.S., Perricone C., Mytilinaiou M.G., Stocker W., Forbes A., Bogdanos D.P. (2016)Background: Pancreatic autoantibodies (PAB) targeting GP2 and CUZD1 are Crohn's disease (CrD)-markers. The clinical significance of anti-GP2 antibodies has been assessed, but that of anti-CUZD1 remains elusive. The aim of ... -
Increased immunoreactivity against human cytomegalovirus UL83 in systemic sclerosis
Marou E., Liaskos C., Efthymiou G., Dardiotis E., Daponte A., Scheper T., Meyer W., Hadjigeorgiou G., Bogdanos D.P., Sakkas L.I. (2017)Objective. To study immunoreactivity against human cytomegalovirus (HCMV) in systemic sclerosis (SSc), since HCMV has been put forward as a candidate infectious cause. Methods. Eighty four patients with SSc (67 females; ...